Financial Performance - Cash and cash equivalents totaled 49.9 million at December 31, 2023, representing a 59% increase[9] - Research and development expenses for the year ended December 31, 2024, were 53.9 million for the year ended December 31, 2023[9] - General and administrative expenses increased to 20.6 million in 2023, marking an increase of approximately 172%[9] - The net loss for the year ended December 31, 2024, was 0.76 per share, compared to a net loss of 1.42 per share, for the year ended December 31, 2023[9] - Total revenue for the year ended December 31, 2024, was 9.99 million in 2023[16] - The accumulated deficit increased to 468.6 million as of December 31, 2023[14] Regulatory and Strategic Developments - The company received a Complete Response Letter from the FDA regarding the New Drug Application for govorestat for Classic Galactosemia, and is evaluating its response[3] - The company is focused on preparing for potential regulatory interactions regarding govorestat in both Classic Galactosemia and SORD Deficiency[2] - The company appointed key senior executives to enhance its regulatory, medical, and quality affairs capabilities, including Todd F. Baumgartner as Chief Regulatory Officer[3] Asset Management - The total assets increased to 54.8 million as of December 31, 2023[14]
Applied Therapeutics(APLT) - 2025 Q1 - Quarterly Results